Abstract: Sustained-release vaginal ring for comprising dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEA-S) or pharmaceutically acceptable thereof as active principle, and optionally a release-modulating agent of the active principle, wherein the amount of active principle is between 1% to 32% by weight, relative to the total weight of the formulation, and the modulator is selected from: polyvinylpyrrolidone K-30, lactose, microcrystalline cellulose and sodium lauryl sulfate. The vaginal ring of the present invention can be used to increase ovarian reserve in women, to be used as drug in assisted reproduction programs, and to relieve symptoms associated with menopause, such as symptoms of vulvar and vaginal atrophy and sexual dysfunction in postmenopausal women.
Type:
Grant
Filed:
December 29, 2011
Date of Patent:
June 30, 2015
Assignees:
Universidad de Chile, Laboratories Andromaco S.A.
Inventors:
Frans Ariel Fuentes Garcia, Shu-Chen Chen, Marianela del Carmen Beltran Apablaza
Abstract: Sustained-release vaginal ring for comprising dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEA-S) or pharmaceutically acceptable thereof as active principle, and optionally a release-modulating agent of the active principle, wherein the amount of active principle is between 1% to 32% by weight, relative to the total weight of the formulation, and the modulator is selected from: polyvinylpyrrolidone K-30, lactose, microcrystalline cellulose and sodium lauryl sulfate. The vaginal ring of the present invention can be used to increase ovarian reserve in women, to be used as drug in assisted reproduction programs, and to relieve symptoms associated with menopause, such as symptoms of vulvar and vaginal atrophy and sexual dysfunction in postmenopausal women.
Type:
Application
Filed:
December 29, 2011
Publication date:
January 1, 2015
Applicants:
UNIVERSIDAD DE CHILE, LABORATORIES ANDROMACO S.A.
Inventors:
Frans Ariel Fuentes Garcia, Shu-Chen Chen, Marianela del Carmen Beltran Apablaza